PDPanagiotis Dragonas

Panagiotis Dragonas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Panagiotis Dragonas has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2020
      • Vol. 13  (3) , 213-232

    Osteogenic capacity of the sinus membrane following maxillary sinus augmentation procedures: A systematic review

    by Panagiotis Dragonas, Theodoros Katsaros, Julie Schiavo, Pablo Galindo-Moreno, Gustavo Avila-Ortiz

    Purpose: The evidence pertaining to the contribution of the sinus membrane to new bone formation following maxillary sinus augmentation procedures is equivocal. The purpose of this study was to analyse the evidence currently available on the osteogenic capacity of the sinus membrane following maxillary sinus augmentation procedures, and the effect of local delivery of recombinant human bone morphogenic proteins (rhBMPs) on the bone-forming potential of the sinus membrane. Materials and methods: An electronic search was conducted using six different databases to identify controlled trials, prospective and retrospective cohort studies, case series and case reports, as well as preclinical (animal) studies reporting on new bone formation in close proximity with the sinus membrane after maxillary sinus augmentation procedures, assessed through histological and/or histomorphometrical evaluation, on the basis of pre-established eligibility criteria. Results: No clinical studies were identified. Twenty-six preclinical studies were included in the review. Nine of them supported the osteogenic potential of the sinus membrane, while eight reported no evidence of osteogenicity from the sinus membrane. The nine remaining studies reported on the local effect of rhBMPs. The majority of these nine studies reported enhanced new bone formation in the sinus membrane region. Conclusions: The sinus membrane contains pluripotent mesenchymal cells with the capacity to differentiate and participate in the process of new bone formation. However, the findings from the studies selected in this systematic review do not consistently support that the sinus membrane significantly contributes to new bone formation following maxillary sinus augmentation procedures.


  • Open Access

    Association of Vitamin D With Periodontal Disease: A Narrative Review

    by Panagiotis Dragonas, Iosif El-Sioufi, Yiorgos A. Bobetsis, Phoebus N. Madianos

    Purpose: To present a review of available literature on the association of vitamin D and periodontal disease. Materials and Methods: A thorough search of articles was carried out on the databases PUBMED and MEDLINE regarding vitamin D and periodontal disease. The selected literature included ...


  • Open Access

    One-year implant survival following lateral window sinus augmentation using plasma rich in growth factors (PRGF): a retrospective study

    by P. Dragonas, M. Foote, Q. Yu, A. Palaiologou, P. Maney

    Background: The aim of this study was to assess one-year implant survival after lateral window sinus augmentation using PRGF combined with various bone grafting materials. Material and Methods: This was a retrospective chart review and radiographic analysis of patients that had undergone lateral window sinus augmentation with PRGF and had dental implants placed at least 6 months post augmentation. All implants included were followed up for at least one year after placement. Demographic, sinus and implant related characteristics (residual ridge height, sinus membrane perforation, type of graft material, implant length and width and ISQ at placement) were analyzed. Results: A total of 31 patients with 39 sinus augmentations and 48 implants were included. The mean follow up was 22.8 +/- 9.9 months. Implant survival was 95.8%, with 2 implants overall failing. Among all the variables assessed, the only one found to be associated with an increased risk for implant failure was the use of xenograft as bone grafting material in the sinus. Conclusions: Within the limitations of this study, dental implants placed in maxillary sinuses grafted with PRGF in combination with bone grafting materials, exhibit high implant survival rates after at least one year follow up.


  • Plasma rich in growth factors (PRGF) in intraoral bone grafting procedures: A systematic review

    by Panagiotis Dragonas, Julie H. Schiavo, Gustavo Avila-Ortiz, Archontia Palaiologou, Theodoros Katsaros


  • Complications Associated With the Use of Recombinant Human Bone Morphogenic Protein–2 in Ridge Augmentation: A Case Report

    by Panagiotis Dragonas, Charles Palin, Saba Khan, Praveen K. Gajendrareddy, Whitney D. Weiner

    This case report aims to describe in detail a complication associated with resorption of regenerated bone following implant placement and ridge augmentation using recombinant human bone morphogenic protein–2 (rhBMP-2) in combination with allograft and xenograft. Bilateral maxillary sinus and ridge augmentation procedures were completed using rhBMP-2 combined with allograft and xenograft. Five months later, significant bone augmentation was achieved, which allowed for the placement of 4 implants. Upon stage 2 surgery, significant dehiscence was noted in all implants. Treatment steps to address this complication included implant removal, guided bone regeneration with xenograft only, and placement of new implants followed by soft-tissue grafting. At the time of publication, this patient is status 1½ years post case completion with maintenance of therapy outcomes. Off-label use of rhBMP-2 has gained significant acceptance in implant dentistry. However, there is limited evidence regarding the bone maturation process when rhBMP-2 is combined with other biomaterials. More research may be needed regarding the timing and process of bone healing in the presence of rhBMP-2, in an effort to avoid surgical complications.